Results 31 to 40 of about 10,858 (213)

Phosphonoamidate prodrugs of C5-substituted pyrimidine acyclic nucleosides for antiviral therapy [PDF]

open access: yes, 2017
Acyclic nucleoside phosphonates (ANPs) are nowadays one of the key drugs in the treatment of DNA virus and retrovirus infections. In this work, we report the synthesis and antiviral evaluation of phosphonoamidate and diamidates prodrugs of C5-pyrimidine ...
Albadry, Najmiyah   +4 more
core   +2 more sources

Entecavir‐induced neutropenia in an adult living donor liver transplant recipient: Successful conversion to tenofovir alafenamide

open access: yesClinical Case Reports, 2023
Key Clinical Message At 22 weeks post‐transplantation for HBV‐related cirrhosis, an adult woman developed neutropenia which was aggravated by COVID‐19 (ANC 0.4 × 109/L). Covid resolution and all “conventional” modifications were ineffective.
I. Vern Lim   +5 more
doaj   +1 more source

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide

open access: yesDrugs in Context, 2021
Although tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) have been evaluated in various clinical trials, limited safety and efficacy data exist in real-world settings.
Sarah M Michienzi   +6 more
doaj   +1 more source

Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerance [PDF]

open access: yes, 2017
[Abstract] Two integrase inhibitors (INSTIs), dolutegravir (DTG) and elvitegravir/cobicistat (EVG/COBI), have joined recently the pharmacotherapy arsenal against HIV.
Balboa Barreiro, Vanesa   +8 more
core   +2 more sources

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2023
Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are prodrugs of the nucleotide analogue tenofovir, which acts intracellularly to inhibit HIV replication.
Aida N. Kawuma   +8 more
doaj   +1 more source

Stability-indicating method development and validation for the concurrent determination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide by UPLC in bulk and tablet dosage forms

open access: yesFuture Journal of Pharmaceutical Sciences, 2021
Background Tablet dosage forms containing combination of darunavir a protease inhibitor, cobicistat a cytochrome P450 3A inhibitor, emtricitabine and tenofovir alafenamide which were nucleoside reverse transcriptase inhibitors were approved by USFDA on ...
M. Satya Venkata Sakuntala   +2 more
doaj   +1 more source

Phosphoramidates and phosphonamidates (ProTides) with antiviral activity [PDF]

open access: yes, 2018
Following the first report on the nucleoside phosphoramidate (ProTide) prodrug approach in 1990 by Chris McGuigan, the extensive investigation of ProTide technology has begun in many laboratories.
Arbelo RC   +9 more
core   +2 more sources

Tenofovir alafenamide clinical pharmacology

open access: yesInfezioni in Medicina, 2021
Tenofovir today exists in two pharmaceutical forms, such as Tenofovir disoproxil fumarate (TDF) and the newer Tenofovir alafenamide (TAF). The two different salts are required in order to promote intestinal absorption of the active molecule (TFV).
openaire   +2 more sources

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide

open access: yesJournal of the International Association of Providers of AIDS Care, 2020
HIV is a serious chronic medical condition. Significant improvements in antiretroviral therapy have led to a transformation in its management. No curative treatment is available for HIV, and lifelong therapy is required with a combination of agents to ...
Chanie Wassner PharmD, BCCCP, BCIDP   +2 more
doaj   +1 more source

Bictegravir, Emtricitabine & Tenofovir Alafenamide-associated Acute Pancreatitis

open access: yesTranslation, 2023
Please view the PDF to see the formatted meeting abstract.
Abdulmajeed Alharbi
doaj   +1 more source

Home - About - Disclaimer - Privacy